Managing acute COVID-19 in immunocompromised pediatric patients.

treatment in pediatric patients retrace the therapies investigated and approved in the adults and must be calibrated on the basis of the severity of the infection (anti-Spike monoclonal antibody, antivirals, antiinflammatory drugs and immunomodulators). Transmission prevention policies and vaccination reduce the risk of infection while early intervention in the immunocompromised patients at high-risk of progression to severe-critical COVID-19 May reduce the period of viral shedding and the need for hospitalization, intensive care admission and death. In hemato-oncological patients, the delaying treatment for SARS-CoV-2 infection or COVID-19 disease represents a frequent complication and its impact on the patient outcome remains a matter of research for the next few years.